Clinical Trial

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

Name: A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL — clinical trial record (NCT06314828)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Record status

This record was last updated March 18, 2024 (before its estimated May 20, 2025 completion). Its status may not reflect the trial's current state.

Summary

This is a Phase 1, open-label, single-arm study to evaluate tolerability, safety and efficacy of RJMty19 in adult subjects with r/r B-NHL.

Trial Details

NCT Number	NCT06314828
Lead Sponsor	Guangdong Ruishun Biotech Co., Ltd Collaborators: Ruijin Hospital, Southern Medical University, China, Beijing GoBroad Hospital
Conditions	B-cell Non-Hodgkin's Lymphoma
Enrollment	30 participants
Start Date	2024-05-20
Primary Completion	2025-05-20 (estimated)
Study Completion	2027-05-20 (estimated)
Updated on ClinicalTrials.gov	2024-03-18